Navigation Links
Anemia from Malaria Linked to a Protein MIF

Scientists at Johns Hopkins, Yale and other institutions have conducted a joint cell and animal study that has revealed one important contributor to the severe anemia// that result from malaria, often causing death.

The culprit is a protein cells make in response to inflammation called MIF, which appears to suppress red blood cell production in people whose red blood cells already are infected by malaria parasites.

The parasite that causes malaria - known as plasmodium - is carried through blood by mosquito bites, and in parts of the world where mosquitoes thrive, millions are infected, most of them by early childhood. Once in the bloodstream, plasmodium invades liver and red blood cells and makes more copies of itself. Eventually, as red cells break and free plasmodium to infect other cells, and as the body's immune system works to kill infected cells, the total number of red blood cells drops, causing anemia.

But not everyone infected with malaria develops severe, lethal anemia. And there are cases where patients who have been cured of infection still develop severe anemia. This report provides the rationale for a simple, genetic test to sort out which children may be most susceptible to this lethal complication of malarial infection and to identify treatments targeted to them especially, the study's authors suggest.

"This is important because in places where malaria is endemic, drug treatment resources are scarce," says the study's primary author, Michael A. McDevitt, M.D., Ph.D., an assistant professor of medicine and hematology at the Johns Hopkins School of Medicine.

"There are many difficulties with blood transfusion safety and access in Africa, especially in rural areas where most of the malaria-related deaths occur," says McDevitt. "That led us to search for a better way to identify those most at risk and a better way to treat the disease," he says. The study, published online April 24 in the Journal of E xperimental Medicine, adds to a growing amount of evidence that an individual's unique genetic makeup can affect the prevalence and outcome of diseases, in this case the individual risk of malarial anemia.

A number of human proteins, including MIF (which stands for migration inhibitory factor), were long suspected to cause malarial anemia because they are known to reduce red blood cell counts as part of the body's normal response to such inflammatory conditions as rheumatoid arthritis or some cancers.

Using immature blood cell precursors grown in a dish, the research team showed that adding MIF to the cells decreases both the final number and maturity of red blood cells. The researchers believe this effect can lead to anemia.

When infected with plasmodium, mice genetically engineered to lack MIF experience less severe anemia and are more likely to survive. Without MIF around to prevent blood cells from maturing, the mice appear better able to maintain their oxygen carrying capacity and don't lose as much hemoglobin, the protein found in red blood cells responsible for binding to oxygen molecules.

"Demonstrating that MIF clearly contributes to severe anemia suggests new ideas for therapies that can block MIF in malaria patients," says the study's senior author, Richard Bucala, M.D., Ph.D., a professor of medicine at Yale University School of Medicine.

The research team also found different versions of "promoter" DNA sequences next to the MIF gene that control how much MIF protein a cell makes in response to infection. One version of the MIF promoter leads to less MIF protein made, while cells containing another version of the MIF promoter make much more MIF protein. Differences in the MIF promoter also have been linked to the severity of other inflammatory diseases.

The researchers continue to collaborate in an effort to develop drugs that might block MIF and treat severe anemia in malaria patients.

Source: Eurekalert
'"/>




Related medicine news :

1. Anemia may Lead to Physical Decline
2. Anemia Treatment for Cancer Patients
3. Anemia Treatment for Cancer Patients
4. Anemia Treatment for Cancer Patients Might Not be a Good Idea.
5. Acute Toxicity Of Nano-Scale Zinc Powder: Severe Renal Damage And Anemia
6. Treatment of Sickle Cell Anemia Using Gene Therapy.
7. Treating Sickle Cell Anemia using Healthy Stem Cells
8. EPO Effective For Cancer Patients Suffering From Anemia
9. Amgen introduces Autoinjector For Treating Anemia
10. Anemia Affects Both Body and Mind
11. Exercise alleviates Anemia in Breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/21/2017)... ... ... As recently as 2015, rhinoplasty was one of the Top 5 cosmetic ... patients want to make a change in the appearance of their nose while others ... team at usrhinoplasty.org is expanding its article database to better inform its ...
(Date:2/21/2017)... ... 2017 , ... American Veterinarian™, the premier multimedia provider of ... first bi-monthly issue of 2017 in February. The inaugural issue will offer expert ... , In making the announcement, American Veterinarian™ Publisher Chris Hennessy said, “We ...
(Date:2/21/2017)... San Francisco, California (PRWEB) , ... February 21, ... ... in the world with over 50,000 participants. The connected care demonstration spanned ... Office of the National Coordinator, roughly 30% of providers have no Health Information ...
(Date:2/21/2017)... ... February 21, 2017 , ... Along with Valentine’s Day, February marks ... small changes that can lead to a lifetime of heart health. In addition, ... emergency. , The Athletic Trainers’ Society of New Jersey (ATSNJ) is urging ...
(Date:2/20/2017)... ... 20, 2017 , ... Daily Body Restore, "DBR" a company ... “good” bacteria in the body, announced its Daily Body Restore® supplement is now ... Body Restore® is made with a unique combination of digestive enzymes and probiotics ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... 21, 2017 Mass Spectrometer Market: Overview ... This report on mass spectrometer ... prospects of the market globally. The stakeholders of ... the manufacture and commercialization of various mass spectrometer ... planning to enter this market. This report comprises ...
(Date:2/21/2017)... -- Luminex Corporation (NASDAQ: LMNX ) (the "Company") today ... of a quarterly cash dividend to its shareholders, the first ... payable on April 14, 2017 to shareholders of record as ... The board of directors intends for the Company ... holders of its common stock, representing a planned annual dividend ...
(Date:2/21/2017)... Feb. 21, 2017  Global health services company Cigna ... ® for breast reconstruction surgery and Dermacell ... an advanced acellular dermal matrix developed by LifeNet Health ... NVDQ ) "We are proud ... health-care payers to review the growing base of evidentiary ...
Breaking Medicine Technology: